NCT00974272

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Carl T. Hayden VA Medical Center · Federal
• Sex: All
• Age: 35 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The primary goal of this study is to determine the acute effects of exenatide on postprandial hypertriglyceridemia. Secondary goals are to determine whether there are additional improvements in postprandial lipids and lipoproteins and whether (by the reduction of hyperglycemia alone or in combination with declines in hyperlipidemia) exenatide reduces the pro-inflammatory potential of the postprandial period.

Conditions

• Type 2 Diabetes Mellitus
• Impaired Glucose Tolerance

Interventions

Type	Name	Description
DRUG	Exenatide	Single subcutaneous injection (10 μg)
OTHER	Normal Saline	Single subcutaneous injection

Timeline

• Start date: 2006-08-01
• Primary completion: 2008-11-01
• Completion: 2008-11-01
• First posted: 2009-09-10
• Last updated: 2009-09-10

Locations

1 site across 1 country: United States